CD45RA depleted leukocytes

PreclinicalBiologic

PPaul Szabolcs

CD45RA depleted leukocytes is one of 6 biologic programs targeting Sickle Cell Anemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sickle Cell AnemiaRecruiting

Sickle Cell AnemiaPreclinical

Recruiting

Competition

Competitive Landscape

5 competitors in Sickle Cell Anemia

#DrugCompanyPhaseTrials

Droxia

TTheravia

Phase 3

1 2

Rituxan

Roche

Preclinical

1 3

Fludara

Sanofi

Preclinical

1 4

Tepadina

Jazz Pharmaceuticals

Preclinical

1 5

Campath

GGenzyme, a Sanofi Company

Preclinical

1 6

CD45RA depleted leukocytes

PPaul Szabolcs

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Sickle Cell Anemia

NCT03653338

Clinical

Trials by Indication[1]

Sickle Cell Anemia1 trial

T-Cell Depleted, Alternative Donor Transplant in Pediatric and Adult Patients With Severe Sickle Cell Disease (SCD) and Other Transfusion-Dependent Anemias

Recruiting·PPaul Szabolcs·Preclinical·NCT03653338·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CD45RA depleted leukocytes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD45RA depleted leukocytes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD45RA depleted leukocytes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Paul Szabolcs company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: PPaul Szabolcs

CD45RA depleted leukocytes

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Sickle Cell Anemia1 trial

References

Drug Info

Quick Facts

Related News